PDUFA Date
CGEM: PDUFA: 0001193125-26-411011
February 27, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- February 27, 2027
- Company
- Cullinan Therapeutics, Inc. (CGEM)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
PDUFA Date
PDUFA: 0001193125-26-411011
Other upcoming events for CGEM
Phase 1 StartPhase1_Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia
Phase 2 StartPhase2_Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia